...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.
【24h】

Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.

机译：波生坦对肺动脉高压患者血浆血浆内皮素1的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease with high mortality. An orally active dual endothelin (ET) receptor antagonist, bosentan, has been reported to improve exercise capacity and survival in patients with PAH. Plasma ET-1 concentration is known to be increased in PAH patients; however, the effect of bosentan on ET-1 concentration has not yet been investigated. METHODS AND RESULTS: The concentration of ET-1 after bosentan administration was examined in 7 PAH patients, including 2 primary and 5 secondary cases. They were clinically assessed by pulmonary artery pressure (PAP), 6-min walk distance (6MWD) and plasma brain natriuretic peptide (BNP) concentration. Baseline ET-1 concentration was significantly higher in patients with PAH than in normal individuals (2.19+/-0.71 pg/ml vs 1.45+/-0.10 pg/ml, p<0.05) and was significantly correlated with 6MWD and BNP. A single dose of 62.5 mg bosentan in patients with PAH significantly increased plasma ET-1 concentration to 2.04times the basal concentration (p<0.01) with a peak at 8.1 h. The peak to base ratio of ET-1 after bosentan administration correlated negatively with severity of PAH as assessed by PAP. CONCLUSIONS: The present study is the first study to show that bosentan administration increases plasma ET-1 in patients with PAH. The response of plasma ET-1 to bosentan administration might be useful for determining the severity of PAH.
机译：背景：肺动脉高压（PAH）是一种高死亡率的进行性疾病。据报道，口服活性双重内皮素（ET）受体拮抗剂波生坦可改善PAH患者的运动能力和存活率。已知PAH患者血浆ET-1浓度会增加;然而，尚未研究波生坦对ET-1浓度的影响。方法与结果：对7例PAH患者进行了波生坦给药后ET-1的浓度检查，其中2例为原发性，5例为继发性。他们通过肺动脉压（PAP），6分钟步行距离（6MWD）和血浆脑利钠肽（BNP）浓度进行了临床评估。 PAH患者的基线ET-1浓度显着高于正常人（2.19 +/- 0.71 pg / ml对1.45 +/- 0.10 pg / ml，p <0.05），并与6MWD和BNP显着相关。 PAH患者单次服用62.5 mg波生坦可将血浆ET-1浓度显着提高至基础浓度的2.04倍（p <0.01），在8.1 h达到峰值。波生坦给药后，ET-1的峰碱比与PAH的严重程度呈负相关（通过PAP评估）。结论：本研究是第一项表明波生坦给药可增加PAH患者血浆ET-1的研究。血浆ET-1对波生坦给药的反应可能有助于确定PAH的严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号